Jiangsu Hengrui Medicine
600276.SS
#522
Rank
โ‚น4.510 T
Marketcap
โ‚น679.60
Share price
-0.40%
Change (1 day)
-23.83%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Half-year Reports

Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2026-h1

Half-year Report 2026-h1

Language: English

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2026-h1

Half-year Report 2026-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2025-h1

Half-year Report 2025-h1

Language: English

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2025-h1

Half-year Report 2025-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2024-h1

Half-year Report 2024-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2023-h1

Half-year Report 2023-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2022-h1

Half-year Report 2022-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2021-h1

Half-year Report 2021-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2020-h1

Half-year Report 2020-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2019-h1

Half-year Report 2019-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2018-h1

Half-year Report 2018-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2017-h1

Half-year Report 2017-h1

Language: Chinese

View Half-year Report
Thumbnail Jiangsu Hengrui Medicine
 Half-year Report 2016-h1

Half-year Report 2016-h1

Language: Chinese

View Half-year Report